MY205849A - Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy - Google Patents

Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy

Info

Publication number
MY205849A
MY205849A MYPI2019001798A MYPI2019001798A MY205849A MY 205849 A MY205849 A MY 205849A MY PI2019001798 A MYPI2019001798 A MY PI2019001798A MY PI2019001798 A MYPI2019001798 A MY PI2019001798A MY 205849 A MY205849 A MY 205849A
Authority
MY
Malaysia
Prior art keywords
nephropathy
immunoglobulin
methods
human subject
subject suffering
Prior art date
Application number
MYPI2019001798A
Other languages
English (en)
Inventor
A Demopulos Gregory
John Brunskill Nigel
Dudler Tom
Schwaeble Hans-Wilhelm
Original Assignee
Omeros Corp
Univ Leicester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/399,524 external-priority patent/US10736960B2/en
Priority claimed from US15/470,647 external-priority patent/US20170253667A1/en
Application filed by Omeros Corp, Univ Leicester filed Critical Omeros Corp
Publication of MY205849A publication Critical patent/MY205849A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027New or modified breeds of vertebrates
    • A01K67/0275Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276Knock-out vertebrates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21104Mannan-binding lectin-associated serine protease-2 (3.4.21.104)
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00Genetically modified animals
    • A01K2217/07Animals genetically altered by homologous recombination
    • A01K2217/075Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00Animals characterised by species
    • A01K2227/10Mammal
    • A01K2227/105Murine
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • A01K2267/035Animal model for multifactorial diseases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54F(ab')2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Environmental Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Animal Husbandry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
MYPI2019001798A 2016-10-13 2017-10-12 Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy MY205849A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662407979P 2016-10-13 2016-10-13
US15/399,524 US10736960B2 (en) 2016-01-05 2017-01-05 Methods for inhibiting fibrosis in a subject in need thereof
US15/470,647 US20170253667A1 (en) 2016-01-05 2017-03-27 Methods for inhibiting fibrosis in a subject in need thereof
US201762527926P 2017-06-30 2017-06-30
PCT/US2017/056386 WO2018071701A1 (fr) 2016-10-13 2017-10-12 Méthodes de réduction de la protéinurie chez un sujet humain souffrant d'une néphropathie aux immunoglobulines a

Publications (1)

Publication Number Publication Date
MY205849A true MY205849A (en) 2024-11-15

Family

ID=61906454

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2019001798A MY205849A (en) 2016-10-13 2017-10-12 Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy

Country Status (19)

Country Link
EP (1) EP3525798A4 (fr)
JP (1) JP6893554B2 (fr)
KR (1) KR102348939B1 (fr)
CN (2) CN110177557A (fr)
AU (1) AU2017342428B2 (fr)
BR (1) BR112019007426A2 (fr)
CA (2) CA3210384A1 (fr)
CL (2) CL2019000909A1 (fr)
GE (2) GEP20267856B (fr)
IL (1) IL265981B2 (fr)
JO (1) JOP20190068B1 (fr)
MA (1) MA46541A (fr)
MX (1) MX2019004074A (fr)
MY (1) MY205849A (fr)
PH (1) PH12019500711B1 (fr)
SG (1) SG11201902941UA (fr)
UA (1) UA126908C2 (fr)
WO (1) WO2018071701A1 (fr)
ZA (1) ZA201902933B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111419860A (zh) * 2020-03-19 2020-07-17 长春市儿童医院 一种肾小球分叶状肾病造模方法
CN115215937B (zh) * 2021-04-15 2023-05-26 上海麦济生物技术有限公司 抗人masp-2抗体及其制备方法和应用
US20230265215A1 (en) 2021-12-10 2023-08-24 Omeros Corporation Therapeutic antibodies that bind to the serine protease domain of masp-2 and uses thereof
CN116392488B (zh) * 2023-05-22 2025-03-28 中南大学湘雅医院 一种生物碱化合物在制备防治糖尿病肾病的药物中的应用
CN117016486B (zh) * 2023-07-20 2024-05-14 上海澎立生技医药研究有限公司 一种IgA肾病合并膜性肾病的动物模型构建方法
WO2026026712A1 (fr) * 2024-07-31 2026-02-05 前沿生物药业(南京)股份有限公司 Arnsi pour inhiber l'expression du gene masp2 et son modificateur et son utilisation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE024996T2 (en) * 2003-05-12 2016-01-28 Helion Biotech Aps Anti-MASP-2 antibodies
US20140056873A1 (en) * 2004-06-10 2014-02-27 University Of Leicester Methods for Treating Conditions Associated with MASP-2 Dependent Complement Activation
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US8840893B2 (en) * 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US7626730B2 (en) * 2006-03-31 2009-12-01 Eastman Kodak Company Method of making a multilevel halftone screen
DK2488203T3 (en) * 2009-10-16 2017-03-13 Omeros Corp METHODS OF TREATING DISSEMINATED INTRAVASCULAR COAGULATION BY INHIBITION OF MASP-2 DEPENDENT COMPLEMENT ACTIVATION
US9102721B2 (en) * 2011-01-21 2015-08-11 Fibrogen, Inc. Therapeutic method
US9644035B2 (en) * 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
BR112013025917A2 (pt) * 2011-04-08 2016-12-20 Omeros Corp uso de um anticorpo masp-2 ou fragmento do mesmo que inibe ativação de complemento dependente de masp-2
HUE049154T2 (hu) * 2011-05-04 2020-09-28 Omeros Corp Készítmények a MASP-2-függõ komplement-aktiválás gátlására
NZ629682A (en) * 2013-03-15 2017-03-31 Omeros Corp Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
JP2016539919A (ja) * 2013-10-17 2016-12-22 オメロス コーポレーション Masp−2依存性補体活性化に関連した状態を治療するための方法
KR102528260B1 (ko) * 2016-01-05 2023-05-04 유니버시티 오브 레스터 필요로 하는 대상체에서 섬유증의 억제 방법
JOP20170170B1 (ar) * 2016-08-31 2022-09-15 Omeros Corp صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق

Also Published As

Publication number Publication date
JP2019534271A (ja) 2019-11-28
KR102348939B1 (ko) 2022-01-12
JOP20190068B1 (ar) 2024-12-22
WO2018071701A1 (fr) 2018-04-19
MX2019004074A (es) 2019-06-10
NZ753260A (en) 2021-11-26
CN116726163A (zh) 2023-09-12
KR20190063475A (ko) 2019-06-07
CN110177557A (zh) 2019-08-27
EP3525798A1 (fr) 2019-08-21
IL265981A (en) 2019-06-30
AU2017342428A1 (en) 2019-05-23
MA46541A (fr) 2019-08-21
BR112019007426A2 (pt) 2019-07-02
CA3039927A1 (fr) 2018-04-19
IL265981B1 (en) 2025-01-01
CA3039927C (fr) 2023-10-10
PH12019500711A1 (en) 2019-11-18
GEP20247587B (en) 2024-01-25
SG11201902941UA (en) 2019-05-30
CA3210384A1 (fr) 2018-04-19
UA126908C2 (uk) 2023-02-22
CL2019000909A1 (es) 2019-06-14
CL2019003485A1 (es) 2020-04-13
EP3525798A4 (fr) 2020-07-08
JP6893554B2 (ja) 2021-06-23
PH12019500711B1 (en) 2024-04-17
IL265981B2 (en) 2025-05-01
GEP20267856B (en) 2026-02-10
ZA201902933B (en) 2023-05-31
AU2017342428B2 (en) 2021-02-04
JOP20190068A1 (ar) 2019-04-01

Similar Documents

Publication Publication Date Title
MY205849A (en) Methods for reducing proteinuria in a human subject suffering from immunoglobulin a nephropathy
MX2021005394A (es) Co-formulaciones de anticuerpos anti-gen de activacion de linfocitos 3 (anti-lag3) y anticuerpos anti-muerte programada-1 (anti-pd-1).
MX2024010937A (es) Metodos para la inhibicion de fibrosis en un sujeto en necesidad del mismo.
MX2019013072A (es) Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1.
PH12018502664A1 (en) Variant adeno-associated viruses and methods of using
ZA201708265B (en) Tigit-binding agents and uses thereof
NZ753515A (en) Methods for treatment of cancer comprising tigit-binding agents
DK3858977T3 (da) Stamme til forebyggelse og behandling af stofskiftesygdomme, og brugen heraf
CY1121806T1 (el) Ιμιδαζοπυραζινονες ως αναστολεις pde1
EP4603508A3 (fr) Anticorps anti-fzd et méthodes d'utilisation
NZ727020A (en) Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
PH12018500578A1 (en) Methods of treating inflammatory diseases
PH12018500100A1 (en) Antibodies that bind to sortilin and inhibit the binding of progranulin
MY196448A (en) Anti-Htra1 Antibodies and Methods of use Thereof
CR20200027A (es) Agentes, usos y métodos para el tratamiento
EA202191471A1 (ru) Противовоспалительные полипептиды
MX378940B (es) Trastornos neurodegenerativos.
EP4273165A3 (fr) Anticorps anti-interféron bêta et leurs utilisations
CY1122784T1 (el) Αλογονωμενες κιναζολιν-τηf-αμινες ως αναστολεις του ρdε1
MX2019000429A (es) Anticuerpo dirigido contra s100a9 humanizado y usos del mismo.
HK1216754A1 (zh) 抗-rankl抗体及其使用方法
BR112018012126A2 (pt) ?adjuvante, método para prevenir e/ou tratar uma doença autoimune, e, uso de um adjuvante?
WO2016135462A8 (fr) Traitement
EA201990903A1 (ru) Способ уменьшения протеинурии у человека, страдающего от иммуноглобулин а нефропатии
GB201800986D0 (en) Second Alzheimers treatment